Modern reproductive patterns associated with estrogen receptor positive but not negative breast cancer susceptibility

Evolution, Medicine and Public Health

Volumn 2015, Issue 1, 2015, Pages 52-74

  Aktipis, C Athena ^a,b   Ellis, Bruce J ^c   Nishimura, Katherine K ^a   Hiatt, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c Environmental Research Laboratory   (United States)

Author keywords

Age of first birth; Breast cancer heterogeneity; Cancer evolution; Evolutionary mismatch; Hormoneassociated breast cancer; Parity

Indexed keywords

ESTROGEN RECEPTOR;

AGE DISTRIBUTION; AGE OF FIRST BIRTH; ARTICLE; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; EPIGENETICS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVOLUTIONARY MISMATCH HYPOTHESIS; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; MATERNAL AGE; MENARCHE; PARITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCTION; REPRODUCTIVE PATTERN;

EID: 84942157525     PISSN: None     EISSN: 20506201     Source Type: Journal    
DOI: 10.1093/emph/eou028     Document Type: Article

References (85)

1. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996;17:47-67.
2. Althuis MD, Fergenbaum JH, Garcia-Closas M et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-68.
3. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California cancer Registry. Cancer 2007;109:1721-28.
4. Beaber EF, Holt VL, Malone KE et al. Reproductive factors, age at maximum height, and risk of three histologic types of breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:3427-34.
5. Colditz GA, Rosner BA, Chen WY et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
6. Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010;70:2247-58.
7. Dolle JM, Daling JR, White E et al. Risk factors for triplenegative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18:1157-66.
8. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
9. Koboldt DC, Fulton RS, McLellan MD et al. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
10. Anderson WF, Pfeiffer RM, Dores GM et al. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiology Biomarkers Prev 2006;15:1899-905.
11. Gruvberger S, Ringner M, Chen Y et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61: 5979-84.
12. Nesse RM, Bergstrom CT, Ellison PT et al. Making evolutionary biology a basic science for medicine. Proc Natl Acad Sci USA 2010;107:1800-7.
13. Nesse RM, Williams GC. Evolution and the origins of disease. Sci Am 1998;279:58-65.
14. Williams GC, Nesse RM. The dawn of darwinian medicine. Q Rev Biol 1991;66:1-22.
15. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13.
16. Merlo LF, Pepper JW, Reid BJ et al. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6: 924-35.
17. Aktipis CA, Nesse RM. Evolutionary foundations for cancer biology. Evol Appl 2013;6:144-59.
18. Caulin AF, Maley CC. Peto's paradox: evolution's prescription for cancer prevention. Trends Ecol Evol 2011;26: 175-82.
19. Greaves M, Aktipis CA. Mismatch with our ancestral environments and cancer risk. In: Maley CC, Greaves MS (eds). Frontiers in Cancer Research: Evolutionary Foundations, Revolutionary Directions. Oxford, in press.
20. Goh KL. Changing trends in gastrointestinal disease in the Asia-Pacific region. J Dig Dis 2007;8:179-85.
21. Eaton SB, Pike MC, Short RV et al. Women's reproductive cancers in evolutionary context. Q Rev Biol 1994;69: 353-67.
22. Strassmann BI. Menstrual cycling and breast cancer: an evolutionary perspective. J Women's Health 1999;8: 193-202.
23. Coe K, Steadman L. The human breast and the ancestral reproductive cycle. Human Nat 1995;6:197-220.
24. Jablonski NG, Chaplin G. Colloquium paper: human skin pigmentation as an adaptation to UV radiation. Proc Natl Acad Sci US A 2010;107:8962-68.
25. Peto R, Darby S, DeoHet al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323-29.
26. Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 1993;15:7-16.
27. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol 1994;139:819-35.
28. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
29. Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 1999;10:431-37.
30. Lips E, Mulder L, de Ronde J et al. Neoadjuvant chemotherapy in ER+ HER2±breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 2012;131:827-36.
31. Shoker BS, Jarvis C, Sibson DR et al. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999;188:237-44.
32. Rugo H. Implications for the Clinic. UCSF Breast Oncology Program Scientific Retreat. Jewish Community Center of San Francisco, 2013, Conference presentation, January 24, 2013.
33. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
34. Bao PP, Shu XO, Gao YT et al. Association of hormonerelated characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol 2011;174: 661-71.
35. Britton JA, Gammon MD, Schoenberg JB et al. Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. Am J Epidemiol 2002;156:507-16.
36. Cooper JA, Rohan TE, Cant EL et al. Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer 1989;59:119-25.
37. Cotterchio M, Kreiger N, Theis B et al. Hormonal factors and the risk of breast cancer according to estrogenand progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev 2003;12:1053-60.
38. Gaudet MM, Press MF, Haile RW et al. Risk factors by molecular subtypes of breast cancer across a population- based study of women 56 years or younger. Breast Cancer Res Treat 2011;130:587-97.
39. Hildreth NG, Kelsey JL, Eisenfeld AJ et al. Differences in breast cancer risk factors according to the estrogen receptor level of the tumor. J Natl Cancer Inst 1983;70: 1027-31.
40. Hislop TG, Coldman AJ, Elwood JM et al. Relationship between risk factors for breast cancer and hormonal status. Int J Epidemiol 1986;15:469-76.
41. Huang WY, Newman B, Millikan RC et al. Hormonerelated factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000;151:703-14.
42. Kreiger N, King WD, Rosenberg L et al. Steroid receptor status and the epidemiology of breast cancer. Ann Epidemiol 1991;1:513-23.
43. Ma H, Bernstein L, Ross RK et al. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res 2006;8:R39.
44. McCredie MR, Dite GS, Southey MC et al. Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. Br J Cancer 2003;89: 1661-63.
45. McTiernan A, Thomas DB, Johnson LK et al. Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers. J Natl Cancer Inst 1986;77:849-54.
46. Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109:123-39.
47. Nichols HB, Trentham-Dietz A, Love RR et al. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 2005;14:41-7.
48. Rosenberg LU, Einarsdottir K, Friman EI et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15:2482-88.
49. Rusiecki JA, Holford TR, Zahm SH et al. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev 2005;29: 419-26.
50. Stanford JL, Szklo M, Boring CC et al. A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol 1987;125:184-94.
51. Ursin G, Bernstein L, Lord SJ et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer 2005;93:364-71.
52. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 2010;27:926-31.
53. Yang XR, Sherman ME, Rimm DL et al. Differences in risk factors for breast cancer molecular subtypes in a population- based study. Cancer Epidemiol Biomarkers Prev 2007; 16:439-43.
54. Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011;103:250-63.
55. Yoo KY, Tajima K, Miura S et al. Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol 1997; 146:307-14.
56. Iwasaki M, Otani T, Inoue M et al. Role and impact of menstrual and reproductive factors on breast cancer risk in Japan. Eur J Cancer Prev 2007;16:116-23.
57. Ma H, Henderson KD, Sullivan-Halley J et al. Pregnancyrelated factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. Breast Cancer Res 2010;12:R35.
58. Palmer JR, Boggs DA, Wise LA et al. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 2011;20:1883-91.
59. Phipps AI, Buist DS, Malone KE et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011;22:399-405.
60. Phipps AI, Chlebowski RT, Prentice R et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20:454-63.
61. Potter JD, Cerhan JR, Sellers TA et al. Progesterone and estrogen-receptors and mammary neoplasia in the Iowa womens health study: how many kinds of breast-cancer are there. Cancer Epidemiol Biomarkers Prev 1995;4: 319-26.
62. Wohlfahrt J, Mouridsen H, Andersen PK et al. Reproductive risk factors for breast cancer by receptor status, histology, laterality and location. Int J Cancer 1999;81: 49-55.
63. Althuis MD, Brogan DD, Coates RJ et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003;14:151-60.
64. Setiawan VW, Monroe KR, Wilkens LR et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 2009; 169:1251-59.
65. Zhu K, Beiler J, Hunter S et al. The relationship between menstrual factors and breast cancer according to estrogen receptor status of tumor: a case-control study in African- American women. Ethn Dis 2002;12:S3-S23.
66. Campbell MJ, Tonlaar NY, Garwood ER et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 2011;128:703-11.
67. Maiti B, Kundranda MN, Spiro TP et al. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 2010;121:479-83.
68. Antoniou AC, Wang XS, Fredericksen ZS et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010; 42:885-92.
69. Stefansson OA, Jonasson JG, Olafsdottir K et al. CpG island hypermethylation of BRCA1 and loss of pRb as cooccurring events in basal/triple-negative breast cancer. Epigenetics 2011;6:638-49.
70. Archey WB, McEachern KA, Robson M et al. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene 2002;21:7034-41.
71. Huynh KT, Chong KK, Greenberg ES et al. Epigenetics of estrogen receptor-negative primary breast cancer. Expert Rev Mol Diagn 2012;12:371-82.
72. Champagne FA. Epigenetic influence of social experiences across the lifespan. Dev Psychobiol 2010;52:299-311.
73. Roth TL, Sweatt JD. Epigenetic mechanisms and environmental shaping of the brain during sensitive periods of development. J Child Psychol Psychiatry 2011;52: 398-408.
74. Robinson GE, Fernald RD, Clayton DF. Genes and social behavior. Science 2008;322:896-900.
75. Weaver ICG, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004;7: 847-54.
76. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Neuroimmunomodulation Health Dis I 2012;1261:55-63.
77. Volden PA, Wonder EL, Skor MN et al. Chronic social isolation is associated with metabolic gene expression changes specific to mammary adipose tissue. Cancer Prev Res 2013;6:634-45.
78. Sieh W, Koebel M, Longacre TA et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol 2013;14: 853-62.
79. O'donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010;31:961-67.
80. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010;42: 410-14.
81. Gates MA, Rosner BA, Hecht JL et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010;171:45-53.
82. Coffey DS. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology 2001;57:31-8.
83. Alvarado LC. Do evolutionary life-history trade-offs influence prostate cancer risk? a review of population variation in testosterone levels and prostate cancer disparities. Evol Appl 2013;6:117-33.
84. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
85. The Cochrane Collaboration. (2012) Review Manager (RevMan). Copenhagen, Denmark: The Nordic Cochrane Centre, 2012.